Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5025,144.30.44%H 25,246.35 · L 25,054.4as of 13 Nov, 3:31 PM IST|Sensex81,592.450.35%H 81,879.51 · L 81,288.75as of 13 Nov, 3:32 PM IST|Bank Nifty61,034.10.4%H 61,300.55 · L 60,780.55as of 13 Nov, 3:31 PM IST|USD / INR₹94.230.2%H ₹94.28 · L ₹94.03as of 13 Nov, 8:09 PM IST|Gold Intl (10g)₹1,17,846.960.12%H ₹1,18,976.98 · L ₹1,17,277.4as of 13 Nov, 11:52 PM IST|Silver Intl (1kg)₹1,48,781.821.91%H ₹1,53,674.56 · L ₹1,48,024.43as of 13 Nov, 11:52 PM IST|Crude WTI₹8,349.720.15%H ₹8,446.78 · L ₹8,273.39as of 13 Nov, 11:52 PM IST|Bitcoin₹64,93,5053.99%H ₹66,22,944.94 · L ₹63,64,065.06as of 13 Nov, 11:59 PM IST|Ethereum₹1,82,8543.69%H ₹1,86,227.47 · L ₹1,79,480.53as of 13 Nov, 11:59 PM IST|Nifty 5025,144.30.44%H 25,246.35 · L 25,054.4as of 13 Nov, 3:31 PM IST|Sensex81,592.450.35%H 81,879.51 · L 81,288.75as of 13 Nov, 3:32 PM IST|Bank Nifty61,034.10.4%H 61,300.55 · L 60,780.55as of 13 Nov, 3:31 PM IST|USD / INR₹94.230.2%H ₹94.28 · L ₹94.03as of 13 Nov, 8:09 PM IST|Gold Intl (10g)₹1,17,846.960.12%H ₹1,18,976.98 · L ₹1,17,277.4as of 13 Nov, 11:52 PM IST|Silver Intl (1kg)₹1,48,781.821.91%H ₹1,53,674.56 · L ₹1,48,024.43as of 13 Nov, 11:52 PM IST|Crude WTI₹8,349.720.15%H ₹8,446.78 · L ₹8,273.39as of 13 Nov, 11:52 PM IST|Bitcoin₹64,93,5053.99%H ₹66,22,944.94 · L ₹63,64,065.06as of 13 Nov, 11:59 PM IST|Ethereum₹1,82,8543.69%H ₹1,86,227.47 · L ₹1,79,480.53as of 13 Nov, 11:59 PM IST|
0%
Stock MarketBreaking

Molbio Diagnostics Surges 83% Since Listing: Motilal Oswal Issues 'Buy' Rating

Arth Vani DeskPublished: 1 min read
Molbio Diagnostics Surges 83% Since Listing: Motilal Oswal Issues 'Buy' Rating

Source: Mint Markets

Arth Insight · What this means for your wallet

Immediate action
Research Molbio Diagnostics' financials and future growth plans before considering an investment.
  • Your initial investment in Molbio Diagnostics could have grown by over 80% if you participated in the IPO.
  • The stock's rapid rise suggests high investor confidence, but also potential for price corrections.
  • Motilal Oswal's 'Buy' rating indicates potential for further gains, but past performance is not a guarantee of future returns.
Recommended for you
Track live indices, stocks & movers
Open Markets
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

Molbio Diagnostics has delivered massive returns of over 80% within two months of its stock market debut. Brokerage firm Motilal Oswal remains bullish on the stock, citing strong growth potential despite the recent price rally.

Key Highlights
  • ▸Molbio Diagnostics has gained 83% in less than two months since its August debut.
  • ▸The stock rose from an IPO price of ₹807 to over ₹1,475.
  • ▸Motilal Oswal has issued a 'Buy' recommendation despite the recent price surge.
  • ▸The company is gaining traction due to its specialized point-of-care diagnostic solutions.
Key Takeaways
  • ✓Molbio Diagnostics has gained 83% in less than two months since its August debut.
  • ✓The stock rose from an IPO price of ₹807 to over ₹1,475.
  • ✓Motilal Oswal has issued a 'Buy' recommendation despite the recent price surge.
  • ✓The company is gaining traction due to its specialized point-of-care diagnostic solutions.

Molbio Diagnostics, a recent entrant to the Indian stock exchanges, has emerged as a top performer in the healthcare diagnostics space. Since its listing on August 17, the stock has surged by approximately 83%, climbing from its initial public offering (IPO) price of ₹807 to a current market price of ₹1,475.50.

Rapid Growth Post-Listing

The stock's performance is particularly notable given the short timeframe of less than two months. Investors who were allotted shares in the IPO have seen their capital nearly double. This rally reflects strong market confidence in the company's business model and its role in the point-of-care testing segment in India.

Why Motilal Oswal is Bullish

Despite the steep rise in valuation, domestic brokerage firm Motilal Oswal has maintained a positive outlook on the counter. The brokerage suggests that the company's unique positioning in the diagnostics market and its expanding footprint provide further room for upside. While the stock has already surpassed many initial expectations, the institutional interest suggests that the long-term growth story remains intact.

Market Context and Performance

The diagnostics sector in India has seen significant volatility and competition recently. However, Molbio's specialized focus has allowed it to carve out a niche. At the current price of ₹1,475.50, the market is pricing in sustained earnings growth and potential expansion into new testing categories. Retail investors should, however, note that such rapid gains often lead to periods of consolidation or profit-booking.

This report is for informational purposes only and does not constitute financial advice. Consult a SEBI-registered advisor before investing.

Recommended for you
Products related to this story — compare & act
Smart picks
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
14.1%
3Y CAGR
Bharat Mobility IPO
Mainboard · Auto
+20.5%
GMP
View IPO
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
13.8%
3Y CAGR
GreenVolt Energy IPO
Mainboard · Renewables
+13.8%
GMP
View IPO
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
13.2%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
12.8%
3Y CAGR

Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.

Frequently Asked Questions

What was the IPO price of Molbio Diagnostics?

The IPO price of Molbio Diagnostics was ₹807 per share.

How much has the stock gained since its listing?

The stock has gained approximately 83% from its IPO price in less than two months.

What is the current recommendation for Molbio Diagnostics?

Brokerage firm Motilal Oswal has recommended a 'Buy' on the stock, citing further growth potential.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Airtel Payments Bank Eyes IPO in 3-4 Years, Targets ₹10,000 Crore Revenue
IPOBreaking
Stock Market

Airtel Payments Bank Eyes IPO in 3-4 Years, Targets ₹10,000 Crore Revenue

Airtel Payments Bank may launch an Initial Public Offering (IPO) within the next three to four years, according to Sunil Bharti Mittal. The bank aims to significantly expand its financial services business, targeting ₹10,000 crore in revenue and deposits, along with ₹1,000 crore in profit.

2h ago·2 min readListen
Razorpay IPO Gets SEBI Nod: Fintech Aims to Raise ₹5,000 Crore
IPOBreaking
Stock Market

Razorpay IPO Gets SEBI Nod: Fintech Aims to Raise ₹5,000 Crore

Fintech major Razorpay has received approval from SEBI for its initial public offering (IPO), five months after confidentially filing its draft documents. The company reportedly plans to raise approximately ₹5,000 crore (around $600 million) through the public issue.

2h ago·1 min readListen
Sensex Recovers 400 Points from Lows as Nifty Reclaims 25,200 Mark
Breaking
Stock Market

Sensex Recovers 400 Points from Lows as Nifty Reclaims 25,200 Mark

Indian equity benchmarks staged a strong recovery during intraday trading, with the Sensex bouncing back over 400 points from its daily lows. The Nifty 50 successfully climbed back above the crucial 25,200 level, signaling resilience despite initial volatility.

12h ago·1 min readListen
Anthropic IPO: Claude AI Maker Targets $64.4 Billion Fundraising in Mega Public Issue
IPOBreaking
Stock Market

Anthropic IPO: Claude AI Maker Targets $64.4 Billion Fundraising in Mega Public Issue

Anthropic, the artificial intelligence startup behind the Claude chatbot, has commenced its IPO roadshow to raise up to $64.4 billion. The company plans to offer 825 million shares as it seeks to compete with industry leaders like OpenAI and Google.

12h ago·1 min readListen